Proteostasis Therapeutics, Inc.
(NASDAQ GS: PTI)
Attention investors who purchased shares of Proteostasis Therapeutics, Inc. before August 24, 2020:
Rigrodsky & Long is investigating potential claims against the board of directors of Proteostasis Therapeutics, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to merge with Yumanity Therapeutics, Inc.
Rigrodsky & Long, P.A. announces that it is investigating Proteostasis Therapeutics, Inc. (“Proteostasis”) (NASDAQ GS: PTI) regarding possible breaches of fiduciary duties and other violations of law related to Proteostasis’ agreement to merge with Yumanity Therapeutics, Inc. (“Yumanity”). Under the terms of the agreement, Proteostasis will issue a number of shares of Proteostasis common stock to Yumanity shareholders.
If you would like to discuss this investigation and your rights cost and obligation free, please contact Seth D. Rigrodsky or Gina M. Serra toll free at (888) 969-4242 or by e-mail at firstname.lastname@example.org.
Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.
Attorney advertising. Prior results do not guarantee a similar outcome.